Ruben Sebastian

What a few days of M&A activity, with good friends involved. - Today: Merck to acquire Terns (allosteric TKI, leukemia) for $6.7B - Monday: Gilead to acquire Ouro (BCMA TCE, I&I) for $2.2B - Last week: Novartis to acquire Synnovation’s SNV4818 (PI3Ki, breast cancer) for $3B

Belén Garijo, departing CEO of Merck KGaA, will take the helm at Sanofi as its new CEO starting in April 2026 sanofi.com/en/media-room/…

European biotech Agomab files for a Nasdaq IPO. Will we see a surge of news post #JPM26? 🤔 bloomberg.com/news/articles/…

Eikon joins the IPO queue after raising over $1B in private funding since 2019 #JPM26 Aktis (now $AKTS) raised $318M in 2026’s first biotech IPO last week. Predictions for 2026 biotech IPOs are in the 30-40 range biopharmadive.com/news/eikon-ipo…

Another deal coming from $NVS this morning #JPM26 Novartis has entered into a worldwide license agreement with PepLib for an undisclosed peptide-based radioligand therapy asset $50M upfront + undisclosed milestones/royalties peplib.com/news_detail/47…

NVIDIA $NVDA and Lilly $LLY are all-in on AI powered drug discovery #JPM26 investor.lilly.com/news-releases/…

SciNeuro and Novartis $NVS enter into a licensing and collaboration agreement for next-gen therapeutics to treat #Alzheimers Amyloid beta targeted antibody program with a proprietary BBB shuttle technology $165M upfront and up to $1.5B total deal #JPM26 prnewswire.com/news-releases/…

AbbVie $ABBV and RemeGen announce exclusive ex China licensing agreement to develop a PD-1/VEGF bispecific antibody for advanced solid tumors $650M upfront and up to $4.95B total deal #JPM26 news is cautiously warming up news.abbvie.com/2026-01-12-Abb…

Tick tock $RVMD #JPM26 ft.com/content/93b4e8…

NRG Therapeutics is now a clinical-stage company! First participants dosed in the FIH trial of lead candidate NRG5051 developed for #ALS and #Parkinsons This great news comes with the tailwind of the oversubscribed Series B we backed last summer. #JPM26 nrgtherapeutics.com/news/22/51/NRG…

What a year for Aboleris Pharma, now reporting the first patient dosed in Part II of its Phase 1 study of ABO21009, a first-in-class anti-CD45RC mAb for rheumatoid arthritis and other #autoimmune diseases. Flawless clinical execution by the team! #JPM26! prnewswire.com/news-releases/…

Lilly/Ventyx is the second biotech acquisition of the year, after Amgen $AMGN acquisition of UK protein degradation startup Dark Blue Therapeutics for up to $840 million. Dark Blue was developing a small molecule degrader of MLLT1/3 for AML #JPM26 amgen.com/newsroom/press…

Lilly $LLY is buying Ventyx Bio $VTYX for $1.2 billion to advance oral therapies targeting inflammatory-mediated diseases. The #JPM26 news flow dance has started investor.lilly.com/news-releases/…

Our team has great fundraising momentum for @Cycle4Survival! Thanks to all the donors for your contributions and generosity. Would you join us to reach our target? @MSKCancerCenter #BeatRareCancers

I’m joining @Cycle4Survival to raise funds for rare cancer research at @MSKCancerCenter. Cancer has touched our home, as I’m sure it has yours. Funding excellent #research is the only path forward. Please consider donating to make a difference! ⬇️ secure2.convio.net/mskcc/site/TR/…

Great time celebrating the holidays at the @NYSE last night. It was a pleasure to join many colleagues from the #biotech finance & business communities on the iconic NYSE floor. I’m gradually becoming a true New Yorker! Happy holidays everyone! 🥂✨

The dance has begun $ABVX #Abivax #biotech #pharma reuters.com/business/healt…

Earlier coverage👇🏼 x.com/RubenSebas_/st…

Paramount launches a hostile takeover bid for Warner Bros Discovery worth $108.4 billion. It seems that the recent competitive bid in biopharma between $PFE and $NVO for $MTSR has served as an early Christmas inspiration for some CEOs… cnn.com/2025/12/08/bus…